Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program

Digital Asset Direct by Algernon Pharmaceuticals Inc.

Vancouver, BC | January 04, 2023 07:00 AM Pacific Standard Time

Algernon Pharmaceuticals CEO Christopher Moreau joined Proactive to share news that the company has decided to move its psychedelic DMT stroke program into a private company called Algernon NeuroScience. Moreau said AGN Neuro will stay private until it has advanced through to the completion of a Phase 2a stroke study planned for Q4, 2023. Following that, the company will consider a potential direct IPO listing on the NASDAQ.

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com